Rose McNulty

Intrathecal drug administration via lumbar puncture and a spinal access port device led to serious complications in a patient receiving experimental therapy for Niemann-Pick type C.

Niemann-Pick type C has historically been considered a contraindication to liver transplantation due to neurological delays, but a recent case report suggests this thinking may be outdated.

A pan-cancer reference atlas provides a framework for an immune-based patient stratification that study authors expect to be predictive for patient prognosis and immunotherapy response at an elevated level after further studies.

The MScanFit method assessed changes in motor unit configuration in adult patients undergoing treatment for spinal muscular atrophy (SMA).

A review of current molecular and electrophysiological biomarkers in spinal muscular atrophy (SMA) concluded that more exploration is necessary to find noninvasive, yet accurate, measures of disease progression and therapy response.

Autologous tumor lysate particle-loaded dendritic cell (TLPLDC) vaccination is well-tolerated in combination with other immunotherapies, but further research is needed to confirm its efficacy.

A recent study compared intelligence quotient test scores between adult patients with spinal muscular atrophy (SMA) and healthy adults.

New retrospective research found that basal and squamous cell cancers increased by 30% over 15 years.

A novel indwelling subcutaneous intrathecal catheter circumvented the complex spine anatomy of patients with spinal muscular atrophy (SMA), a challenge when giving nusinersen via intrathecal injection.

A large cohort study aimed to find out whether tumor-infiltrating lymphocytes, an important biomarker in melanoma, could be an independent prognostic factor for overall survival.

A review of advances in spinal muscular atrophy (SMA) identification and treatment highlights areas where there is room for improvement.

A retrospective study on the combination of a vascular endothelial growth factor receptor inhibitor plus programmed cell death-1 blockade added to evidence of efficacy in early trials.

Biomarkers for spinal muscular atrophy are needed to further analyze treatment efficacy, and a recent study points to serum neurofilament light chain levels as a possible option.

Pain is a hallmark of many Fabry disease cases, and improvements in management could dramatically improve quality of life for patients.

Despite excellent prognoses in low-risk patients with essential thrombocytopenia (ET) and polycythemia vera (PV), knowledge gaps remain and novel, more tolerable therapies require reevaluation of treatment algorithms.

A review of current research and drug development in motor neuron disorders such as amyotrophic lateral sclerosis and spinal muscular atrophy shows progress in the identification of treatment pathways and therapies.

In patients with BRAF-mutated melanoma, achieving a complete response and circulating tumor DNA negativity are promising prognostic markers.

A review of instruments used to assess upper-limb function in patients with neuromuscular diseases found that more tools are needed to address specific diseases.

A recent review of viral gene therapy in pediatric neurological diseases included positive outcomes in patients with spinal muscular atrophy (SMA).

Combination CDK4/6 and MEK inhibitor treatment reduced tumor growth in mouse models of melanoma with acquired resistance to BRAF and MEK inhibition.

The largest known prospective study of patients treated with trametinib plus dabrafenib for unresectable advanced melanoma with BRAF-V600 mutation confirmed the combination’s clinical activity.

Recent research identified spinal muscular atrophy (SMA)–specific growth percentiles, aiming to improve clinical management of the nutritional aspects of the disease.

A review of current data identified areas of progress in Bruton tyrosine kinase (BTK) inhibition for patients with chronic lymphocytic leukemia (CLL).

A pair of surveys found that there are knowledge and practice gaps preventing earlier diagnoses of spinal muscular atrophy (SMA) in infants and toddlers.

A study of patients given first-line metastatic melanoma treatment showed that utilization rates were highest in patients using ipilimumab-containing therapies.

An epidemiological investigation of spinal muscular atrophy (SMA) in Japan provided clarity on the genetic condition’s prevalence and incidence in the country and highlighted the importance of newborn screening for SMA

AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews. These interviews have been edited lightly for clarity.

Kathryn Gold, MD, medical oncologist and associate professor of medicine at UC San Diego, who is a member of the NCCN guidelines panel for small-cell lung cancer, gives insight into the guidelines and the importance of frequent updates.

At the 2021 Cholangiocarcinoma Foundation Annual Conference, experts discussed clinical trials in cholangiocarcinoma and the ways in which clinical trials overall can be made more available to patients.